Design, Synthesis, Characterization, and In Vitro Evaluation of a New Cross-Linked Hyaluronic Acid for Pharmaceutical and Cosmetic Applications

Pharmaceutics

Sabrina Sciabica¹  Silvia Vertuani¹  Elisa Durini¹  Anna Baldisserotto¹  Stefano Manfredini¹  Giovanni Tafuro²  Alessandra Semenzato²  Luisa Canilli³  Massimo Terno³  Daniela Traini⁴  Larissa Gomes Dos Reis⁴  Dina M. Silva⁴ 

[1] Department of Life Sciences and Biotechnology, University of Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy;Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy;Istituto Ganassini S.p.A., Via Carlo Boncompagni, 63, 20139 Milano, Italy;Macquarie Medical School, Department of Medical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University & Woolcock Institute of Medical Research, Sydney 2037, Australia;

关键词: hyaluronic acid;    cross-linking;    biocompatibility;   

DOI  :  10.3390/pharmaceutics13101672

来源: DOAJ

【 摘 要 】

Hyaluronic acid (HA), an excellent biomaterial with unique bio properties, is currently one of the most interesting polymers for many biomedical and cosmetic applications. However, several of its potential benefits are limited as it is rapidly degraded by hyaluronidase enzymes. To improve the half-life and consequently increase performance, native HA has been modified through cross-linking reactions with a natural and biocompatible amino acid, Ornithine, to overcome the potential toxicity commonly associated with traditional linkers. 2-chloro-dimethoxy-1,3,5-triazine/4-methylmorpholine (CDMT/NMM) was used as an activating agent. The new product (HA–Orn) was extensively characterized to confirm the chemical modification, and rheological analysis showed a gel-like profile. In vitro degradation experiments showed an improved resistance profile against enzymatic digestions. Furthermore, in vitro cytotoxicity studies were performed on lung cell lines (Calu-3 and H441), which showed no cytotoxicity.

【 授权许可】

Unknown